Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BAFF as a Key Modulator of Respiratory Mucosal B Cell Immunity in Viral Infection and Mucosal Vaccination.

Cells·2026
Same author

The Role of Lung Microbiota in Shaping Host Immunity and Mucosal Vaccine Responses.

Vaccines·2026
Same author

Respiratory Syncytial Virus Induces B Cell Activating Factor (BAFF) in Airway Epithelium: A Potential Avenue for Mucosal Vaccine Development.

Viruses·2025
Same author

MERS-CoV Infection and Its Impact on the Expression of TSLP Cytokine and IgG Antibodies: An In Vivo and In Vitro Study.

Infection and drug resistance·2024
Same author

Immunomodulatory effects of BAFF and APRIL cytokines in post-pulmonary infection lung cancer: Implications for drug resistance and progression.

Saudi medical journal·2024
Same author

Antioxidant, LC-MS Analysis, and Cholinesterase Inhibitory Potentials of <i>Phoenix dactylifera</i> Cultivar Khudari: An In Vitro Enzyme Kinetics and In Silico Study.

Biomolecules·2023

Related Experiment Video

Updated: Jun 27, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Codon-Pair Deoptimized (CPD) Intranasal RSV Vaccines: A Novel Strategy for Infant Protection.

Wael Alturaiki1

  • 1Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al-Majmaah 11952, Saudi Arabia.

International Journal of Molecular Sciences
|June 26, 2026
PubMed
Summary

Developing effective respiratory syncytial virus (RSV) vaccines for infants is crucial due to high morbidity. Codon-pair deoptimization (CPD) shows promise for safe and immunogenic live-attenuated RSV vaccines.

Keywords:
CPDRSVinfant immunizationintranasal vaccinelive-attenuated vaccinemucosal immunity

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

Related Experiment Videos

Last Updated: Jun 27, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of infant respiratory infections and mortality worldwide.
  • Past RSV vaccine development faced challenges, including vaccine-enhanced disease and short-lived immunity.
  • Infant immune naivety and lack of clear immunity correlates complicate vaccine design.

Purpose of the Study:

  • To review challenges in developing effective RSV vaccines for infants.
  • To highlight lessons from previous RSV vaccine failures.
  • To discuss recent advances, particularly codon-pair deoptimization (CPD) strategies.

Main Methods:

  • Review of historical RSV vaccine development efforts.
  • Analysis of recent breakthroughs in RSV structural virology and immunology.
  • Evaluation of intranasal live-attenuated vaccine approaches, including CPD.

Main Results:

  • Codon-pair deoptimization (CPD) offers a novel strategy for creating live-attenuated RSV vaccines.
  • CPD-based RSV vaccine candidates demonstrate robust immunogenicity with favorable safety profiles in preclinical studies.
  • Intranasal live-attenuated vaccines mimic natural infection, inducing systemic and mucosal immunity.

Conclusions:

  • Effective RSV immunization for infants remains a critical unmet need.
  • CPD represents a promising approach for developing safe and effective live-attenuated RSV vaccines for infants.
  • Understanding protective immunity, particularly prefusion F protein antibodies, guides future vaccine design.